Title of article :
Structure–activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors Original Research Article
Author/Authors :
Robert M. Rzasa، نويسنده , , Matthew R. Kaller، نويسنده , , Gang Liu، نويسنده , , Ella Magal، نويسنده , , Thomas T. Nguyen، نويسنده , , Timothy D. Osslund، نويسنده , , David Powers، نويسنده , , Vincent J. Santora، نويسنده , , Vellarkad N. Viswanadhan، نويسنده , , Hui-Ling Wang، نويسنده , , Xiaoling Xiong، نويسنده , , Wenge Zhong، نويسنده , , Mark H. Norman، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2007
Pages :
22
From page :
6574
To page :
6595
Abstract :
Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase that plays a critical role in the early development of the nervous system. Deregulation of CDK5 is believed to contribute to the abnormal phosphorylation of various cellular substrates associated with neurodegenerative disorders such as Alzheimer’s disease, amyotrophic lateral sclerosis, and ischemic stroke. Acyclic urea 3 was identified as a potent CDK5 inhibitor and co-crystallographic data of urea 3/CDK2 enzyme were used to design a novel series of 3,4-dihydroquinazolin-2(1H)-ones as CDK5 inhibitors. In this investigation we present our synthetic studies toward this series of compounds and discuss their biological relevance as CDK5 inhibitors.
Keywords :
Neurodegenerative disorders , CDK5 , Kinase inhibitor , 4-Dihydro-1H-quinazolin-2-one , 3
Journal title :
Bioorganic and Medicinal Chemistry
Serial Year :
2007
Journal title :
Bioorganic and Medicinal Chemistry
Record number :
1306040
Link To Document :
بازگشت